In the continually evolving field of dry eye therapies, next up is a nasal spray to address dry eye symptoms.
Oyster Point Pharmaceuticals announced results from their ONSET-2 phase 3 study of their newest product, OC-01 varenicline. This novel nasal spray activates the trigeminal parasympathetic pathway than stimulates the lacrimal functional unit to rebuild the natural tear film.
The study involved 758 patients who received one of two doses of OC-01 nasal spral or placebo twice daily for 28 days. Results showed that almost 50% of the patients treated with OC-01 showed improvement.
VisiVite offers two supplements to help dry eye sufferers: VisiVite Dry Eye Relief and VisiVite Quench.